Evaluating Gender Differences in Egyptian Fibromyalgia Patients Using the 1990, 2011, and 2016 ACR Criteria

Moshrif, A.; Shoaeir, Mohamed Z.; Abbas, Afroze; Abdel-Aziz, Tarek M.; Gouda, Wesam

doi:10.2147/oarrr.s358255

Cited by 13 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The gender difference was noted in the clinical presentation of FM patients (WPI, SSS, TPs), but not in the seropositivity or the CTD diagnoses. The results of the clinical presentation are similar to what was already reported [ 36 ]. However, our study was not powered to evaluate gender differences in seropositivity, enrolling a very low number of male patients.…”

Section: Discussionsupporting

confidence: 90%

Myositis-Specific and Myositis-Associated Antibodies in Fibromyalgia Patients: A Prospective Study

et al. 2023

View full text Add to dashboard Cite

Fibromyalgia (FM) is a common rheumatologic disorder characterised by widespread muscular pain. Myalgia is also a common clinical feature in Connective Tissue Disease (CTD), and FM should be studied for the concomitant presence of a CTD. The aim of this study is to evaluate the prevalence of Myositis-Specific and Myositis-Associated Antibodies (MSA/MAA) in a cohort of FM patients. We enrolled 233 consecutive FM patients (defined according to the 2016 criteria) that did not report clinical signs of autoimmune disorders and followed them for at least one year. The patients were tested for MSA/MAA with immunoblotting. FM patients were seropositive for Antinuclear Antibodies (ANA) in 24% of cases, for MSA in 9%, and for MAA in 6%. A specific diagnosis of CTD was made in 12 patients (5.2%), namely, 5 cases of primary Sjögren’s Syndrome and 7 of Idiopathic Inflammatory Myopathy. Seropositive patients showed clinical features similar to those who were seronegative at baseline. A CTD diagnosis was associated with ANA positivity (p = 0.03, X2 4.9), the presence of a speckled pattern (p = 0.02, X2 5.3), positivity for MAA (p = 0.004, X2 8.1), and MSA (p = 0.003, X2 9.2). In conclusion, a non-negligible proportion of FM patients may be seropositive for MSA/MAA, and that seropositivity might suggest a diagnosis of CTD.

show abstract

Section: Discussionsupporting

confidence: 90%

Myositis-Specific and Myositis-Associated Antibodies in Fibromyalgia Patients: A Prospective Study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…28,29 There was no significant difference between male and female regarding the DD, which is consistent with our recently published work evaluating the gender difference in FM patients considering the different ACR classification criteria. 30 Increased age was substantially linked with DD in our FM patients in the current study, which is similar to previously published findings by Gendelmans et al 31 Furthermore, increasing BMI was associated with a longer DD in FM patients; these findings are consistent with those provided by Gota et al 32 The DD was associated with greater disease severity, fatigue, and tender points. We also found that SSS, WPI, and PDS were greater in patients with DD.…”

supporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

“…The polysymptomatic distress scale (PDS), score range: (0-31) was also evaluated. Based on the PDS, which is the summation of WPI and SSS, the disease severity could be classified as none (0-3), mild (4-7), moderate (8)(9)(10)(11), severe (12)(13)(14)(15)(16)(17)(18)(19), and very severe (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31). 12 The Revised Fibromyalgia Impact Questionnaire (FIQR) 13 includes other symptoms such as cognitive issues, pain, balance, and environmental sensitivity.…”

Section: Demographics and Clinical Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the Effect of Delayed Diagnosis on Disease Outcome in Fibromyalgia: A Multi-Center Cross-Sectional Study

Moshrif¹,

Mosallam²,

Abu-Zaid³

et al. 2023

JPR

Self Cite

View full text Add to dashboard Cite

Background The impact of delayed diagnosis (DD) on fibromyalgia (FM) patients’ symptomatology and disease outcome has not yet been systematically studied. Objective To analyze the predictors of DD and the influence of DD on FM aggravation and disease evaluation measures. Methods 370 FM patients were interviewed prospectively for this study. The following information was obtained: DD, widespread pain index (WPI), symptom severity scale (SSS), polysymptomatic distress scale (PDS) scale (SSS + WPI), and tender points. We identified three groups of patients: early diagnosis (ED: 2 years; 83 patients), late diagnosis (LD: > 2–7 years; 198 patients), and very late diagnosis (VLD: > 7 years; 89 patients). Results The patients’ average age was 33.9 (9.8) years, and 79% were female. The SSS, PDS, and tender point means were 7.8 (1.6), 16.46 (4.1), and 14.31 (2.3), respectively. The correlation between DD and SSS (r = 0.14), the PDS scale (r = 0.37), and FM tender points (r = 0.16) was significant, but not with WPI (r = 0.06). When the three groups were examined, the SSS mean was 7.54 (1.6), 7.73 (1.4), and 8.25 (1.7), respectively (P 0.008), while the PDS mean was 15 (3.8), 15.95 (3.8), and 18.96 (4.4), respectively (P 0.008). (P 0.001). Conclusion Early FM diagnosis is associated with lower SSS, total severity scale, and FM tender points, indicating a less severe condition.

show abstract

“…One possible explanation is hormonal differences between males and females. Female sex hormones, such as estrogen and progesterone, have been shown to modulate pain perception and may play a role in the development of FM 25 , 26 . Women also experience hormonal fluctuations throughout the menstrual cycle, pregnancy, and menopause, which may contribute to the development or exacerbation of FM symptoms 27 .…”

Section: Introductionmentioning

confidence: 99%

Assessment of the therapeutic potential of lutein and beta-carotene nanodispersions in a rat model of fibromyalgia

Elkholy,

Mohammed,

Shafaa

2023

Sci Rep

View full text Add to dashboard Cite

Fibromyalgia (FM) is a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and cognitive impairment. Despite the availability of various treatment options, FM remains a challenging condition to manage. In the present study, we investigated the efficacy of formulated nanodispersions of lutein and beta-carotene in treating FM-related symptoms induced by reserpine in female Wistar rats. Several techniques have been implemented to assess this efficacy at various levels, including biochemical, bioelectrical, and behavioral. Namely, oxidative stress markers, monoamine levels, electrocorticography, pain threshold test, and open field test were conducted on control, FM-induced, and FM-treated groups of animals. Our results provided compelling evidence for the efficacy of carotenoid nanodispersions in treating FM-related symptoms. Specifically, we found that the dual action of the nanodispersion, as both antioxidant and antidepressant, accounted for their beneficial effects in treating FM. With further investigation, nano-carotenoids and particularly nano-lutein could potentially become an effective alternative treatment for patients with FM who do not respond to current treatment options.

show abstract

Evaluating Gender Differences in Egyptian Fibromyalgia Patients Using the 1990, 2011, and 2016 ACR Criteria

Cited by 13 publications

References 33 publications

Myositis-Specific and Myositis-Associated Antibodies in Fibromyalgia Patients: A Prospective Study

Myositis-Specific and Myositis-Associated Antibodies in Fibromyalgia Patients: A Prospective Study

Evaluating the Effect of Delayed Diagnosis on Disease Outcome in Fibromyalgia: A Multi-Center Cross-Sectional Study

Assessment of the therapeutic potential of lutein and beta-carotene nanodispersions in a rat model of fibromyalgia

Contact Info

Product

Resources

About